Translational Research in Oncology announced the first patient was randomized in the REPLACE (TRIO041) trial
Translational Research in Oncology shared on their LinkedIn page:
”TRIO is happy to announce that the first patient was randomized in the REPLACE (TRIO041) trial, a phase 3, randomized, multicenter, global clinical trial of regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC with beyond up-to-7 criteria.
REPLACE, a TRIO-sponsored trial supported by Bayer, is co-chaired by Peter Galle (University Medical Center Mainz, Germany) and Richard Finn (University of California Los Angeles, US). The goal of the trial is to test the hypothesis, in the phase 3 setting, that systemic therapy with regorafenib-pembrolizumab is advantageous over standard locoregional treatment in intermediate-stage HCC with high tumor burden.
TRIO is engaging its global investigator network to initiate sites across 13 countries. More information on the REPLACE (TRIO041) trial can be found here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023